<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chronic spontaneous urticaria: Treatment of refractory symptoms
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chronic spontaneous urticaria: Treatment of refractory symptoms
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chronic spontaneous urticaria: Treatment of refractory symptoms
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David A Khan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sarbjit Saini, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria, is defined by the presence of urticaria (hives) on most days of the week for a duration of six weeks or longer [
         <a href="#rid1">
          1
         </a>
         ]. Associated angioedema occurs in approximately 40 percent of patients. Standard management of CSU primarily involves second-generation H1 antihistamines, often at higher-than-usual doses and in combination with H2 antihistamines and leukotriene modifiers. Short courses of systemic glucocorticoids to control severe exacerbations may be needed. This topic discusses the treatment of patients whose symptoms are not controlled over time using these standard therapies.
        </p>
        <p>
         Therapeutic options for patients with refractory CSU will be reviewed here, as well as the evidence in support of the efficacy of each treatment. Standard management, as well as the diagnosis, pathogenesis, and prognosis of CSU, are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/8106.html" rel="external">
          "Chronic spontaneous urticaria: Standard management and patient education"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">
          "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history"
         </a>
         .)
        </p>
        <p>
         Urticarial vasculitis and specific physical forms of chronic urticaria, such as delayed-pressure urticaria, cholinergic urticaria, or cold urticaria, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">
          "Urticarial vasculitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8109.html" rel="external">
          "Physical (inducible) forms of urticaria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8102.html" rel="external">
          "Cold urticaria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H737135331">
         <span class="h1">
          REFERRAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with recurrent urticaria with or without angioedema that continues to recur for a period of six weeks or longer and cannot be adequately controlled with higher doses of second-generation H1 antihistamines should be referred to an allergy or dermatology specialist. These patients are at risk for receiving repeated courses of oral glucocorticoids. However, long-term systemic glucocorticoids have potentially severe side effects and do not appear to induce lasting remission or alter the natural history of CSU. Thus, it is preferable to limit glucocorticoid use to short periods of the minimally effective doses and to refer the patient for consideration of more advanced treatments before they have been exposed to months of glucocorticoid therapy. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
         In some cases, immunosuppressant or antiinflammatory drugs are needed, and it is important for the treating specialist to be knowledgeable about potential adverse effects and monitoring when administering the agents discussed in this topic. Consultation with additional specialists (eg, rheumatologists) may be appropriate, depending on the medication, as well as the experience and comfort level of the treating specialist.
        </p>
        <p class="headingAnchor" id="H1919908">
         <span class="h1">
          OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         Available data indicate that H1 antihistamines at higher-than-standard doses will adequately control CSU symptoms in approximately one-half of patients, and a small number will get additional benefit from the other well-tolerated and low-risk supplementary therapies (eg, H2 antihistamines and
         <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">
          montelukast
         </a>
         ). The efficacy of H1 antihistamine therapy for CSU is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/8106.html" rel="external">
          "Chronic spontaneous urticaria: Standard management and patient education", section on 'H1 antihistamines'
         </a>
         .)
        </p>
        <p>
         For patients inadequately controlled on high-dose H1 antihistamines, international guidelines recommend treatment with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         [
         <a href="#rid2">
          2
         </a>
         ]. For patients refractory to standard doses of omalizumab, dosing adjustments of omalizumab are recommended prior to consideration of other medications such as
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and several additional drugs that have either antiinflammatory or immunosuppressant effects. The recommendations in this topic review are generally consistent with guidelines from international societies [
         <a href="#rid1">
          1-5
         </a>
         ]. Deviations from the recommendations in the guidelines are noted.
        </p>
        <p>
         When introducing these more advanced treatments, antihistamines and other standard agents that were clearly helpful to the patient are typically continued. Any medications of uncertain benefit should be discontinued so that medications do not accumulate.
        </p>
        <p class="headingAnchor" id="H22593276">
         <span class="h2">
          Goal of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of therapy in patients with refractory CSU is to achieve a level of symptom control and improvement in quality of life that is acceptable to the patient, while minimizing therapy-related side effects. Patients differ in their preferences. Some want to pursue complete control, while others would rather minimize medications and accept a low level of ongoing symptoms. In addition, it should be kept in mind that although CSU can be a disabling disorder, it does not lead to permanent organ damage, and it ultimately resolves in the majority of patients, with or without treatment. Thus, a treatment that appears to be inducing serious adverse side effects is not warranted. The natural history of CSU is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">
          "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history", section on 'Natural history and prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1920133">
         <span class="h2">
          Choice of initial intervention
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients whose symptoms cannot be adequately controlled by higher-dose antihistamines, international guidelines recommend the addition of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , a monoclonal antibody against immunoglobulin E (IgE), as the most appropriate next intervention [
         <a href="#rid1">
          1
         </a>
         ]. Omalizumab is preferred because of both proven efficacy and also safety relative to immunosuppressant or antiinflammatory drugs. However, the high cost of omalizumab is a concern in all health care systems and will limit the use of this therapy in many settings. (See
         <a class="local">
          'Omalizumab'
         </a>
         below.)
        </p>
        <p>
         We agree with international guidelines that
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         is the most appropriate therapy for patients who do not respond to higher-dose H1 antihistamine therapy [
         <a href="#rid1">
          1
         </a>
         ]. However, we typically give up-dosing of antihistamines a trial period of at least several weeks to fully assess effectiveness, whereas the international guidelines suggest that the trial period for antihistamines can be as short as one month  (
         <a class="graphic graphic_algorithm graphicRef118731" href="/z/d/graphic/118731.html" rel="external">
          algorithm 1
         </a>
         ). Up-dosing of antihistamines is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/8106.html" rel="external">
          "Chronic spontaneous urticaria: Standard management and patient education", section on 'Up-dosing of second-generation agents'
         </a>
         .)
        </p>
        <p>
         Several studies have examined potential biomarkers to predict response to various therapies for refractory CSU, but none can be recommended for routine clinical use [
         <a href="#rid6">
          6
         </a>
         ]. The most promising developments have been in identification of possible biomarkers to predict responsiveness to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         [
         <a href="#rid7">
          7-9
         </a>
         ]. (See
         <a class="local">
          'Predicting responsiveness'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H22592681">
         <span class="h1">
          OMALIZUMAB
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         is a monoclonal antibody directed against IgE, which was approved in the United States in 2014 for the treatment of patients 12 years of age and older with CSU that is not controlled with standard-dose H1 antihistamine therapy [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/108976.html" rel="external">
          "Society guideline links: Urticaria and angioedema (excluding hereditary angioedema)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H920830710">
         <span class="h2">
          Predicting responsiveness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies have identified potential biomarkers that may predict responsiveness to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         therapy, but none predict a response well enough to inform the decision to treat. No specific laboratories are required before omalizumab is initiated for CSU.
        </p>
        <p>
         A 2022 study of 23 CSU patients treated with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         found that low serum trough concentrations of omalizumab were associated with worse responsiveness [
         <a href="#rid11">
          11
         </a>
         ]. In addition, higher body mass index (BMI) was a significant predictor of low serum omalizumab concentrations, suggesting that some patients with higher BMI may need higher doses or more frequent doses of omalizumab. (See
         <a class="local">
          'Dose adjustment and duration of therapy'
         </a>
         below.)
        </p>
        <p>
         Other possible predictors of a better response include higher baseline serum IgE levels [
         <a href="#rid8">
          8,12
         </a>
         ], a greater than twofold increase in IgE after four weeks of treatment compared with baseline IgE [
         <a href="#rid8">
          8
         </a>
         ], higher baseline levels of high-affinity IgE receptor (Fc-epsilon-RI) on blood basophils, and greater reduction of Fc-epsilon-RI on basophils after four weeks of treatment [
         <a href="#rid9">
          9
         </a>
         ]. However, serum IgE levels predict basophil IgE receptor levels, so these biomarkers are interconnected, and further study is needed.
        </p>
        <p class="headingAnchor" id="H11163884">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A meta-analysis of seven randomized trials (1312 patients) demonstrated that
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         significantly reduced the weekly itch and wheal scores relative to placebo in patients with CSU not responsive to standard doses of H1 antihistamines (eg,
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         10 mg daily) [
         <a href="#rid13">
          13-21
         </a>
         ]. The most effective dose was 300 mg every four weeks, at which 36 percent of patients had a complete response (urticaria activity score of 0). Adverse event rates and specific events were similar with omalizumab and placebo. Other analyses of multiple studies showed that omalizumab improved sleep beginning after the first dose and provided substantial improvements in quality of life [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
         One trial included in the meta-analysis was particularly informative because it closely approximated common clinical practice. The GLACIAL trial evaluated 335 patients whose symptoms were not controlled with H1 antihistamines (up to four times the standard dose) plus H2 antihistamines, antileukotriene agents, or the combination [
         <a href="#rid17">
          17
         </a>
         ]. Subjects were randomized to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , 300 mg monthly, or placebo. Baseline medications were continued unchanged throughout the study period and the four-month follow-up period. The primary endpoint was a change in mean weekly itch severity scores (on a scale from 0 to 21, with a minimally important difference of 5) at the end of 12 weeks. Clinical efficacy was apparent by one week in the omalizumab group. Mean itch scores decreased a clinically meaningful amount only in the omalizumab group, and the difference between the two groups was statistically significant. A minimally important difference in symptoms was achieved by 70 and 40 percent of subjects in the omalizumab and placebo groups, respectively. At 12 weeks, 34 and 5 percent of subjects were itch and hive free in the omalizumab and placebo groups, respectively. Once omalizumab was stopped, subjects' symptoms gradually returned during the observation period and were similar to placebo at the end of the study. Thus, the addition of omalizumab to the combination of maximally dosed H1 antihistamines (with or without H2 antihistamines, antileukotriene agents, or both) will control symptoms in another 30 to 35 percent of patients, and the combination of maximal antihistamine therapy plus omalizumab will achieve satisfactory control of CSU in approximately 80 percent of patients.
        </p>
        <p class="headingAnchor" id="H2659878271">
         <span class="h2">
          Long-term impact
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         has not been shown to have a long-term disease-modifying effect, so patients may relapse when omalizumab is tapered or discontinued [
         <a href="#rid24">
          24
         </a>
         ]. However, CSU is a disorder that remits or resolves in the majority of patients within a few years even untreated, so it can be difficult to assess the impact of therapy on natural history. (See
         <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">
          "Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history", section on 'Natural history and prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3933520678">
         <span class="h2">
          Safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among all nonantihistamine therapies with proven efficacy for refractory CSU,
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         is the best studied, most widely used therapy and has a very low incidence of serious adverse effects. It has been used safely in pregnant women and is the treatment of choice for refractory CSU during pregnancy [
         <a href="#rid25">
          25,26
         </a>
         ]. The adverse effects of omalizumab are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/545.html" rel="external">
          "Anti-IgE therapy", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3574989876">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         No specific laboratory monitoring is required for patients receiving
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         for CSU.
        </p>
        <p class="headingAnchor" id="H298664591">
         <span class="h2">
          Our approach
         </span>
        </p>
        <p class="headingAnchor" id="H736903988">
         <span class="h3">
          Initial dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         We initiate
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         at a dose of 300 mg injected subcutaneously every four weeks based on studies of efficacy that evaluated different dosing approaches, as well as recommendations from international guidelines [
         <a href="#rid2">
          2,13,18
         </a>
         ]. We continue nonsedating H1 antihistamines initially and then taper as tolerated if the patient responds well to omalizumab. Patients must be prescribed an
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         autoinjector because anaphylaxis is reported, although not at rates any higher than with other biologic therapies. (See
         <a class="medical medical_review" href="/z/d/html/545.html" rel="external">
          "Anti-IgE therapy", section on 'Anaphylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3854441626">
         <span class="h3">
          Expected response
         </span>
         <span class="headingEndMark">
          —
         </span>
         In an analysis of multiple trials intended to evaluate the extent and time course of the response to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , approximately 60 percent of patients had a meaningful reduction in symptoms by week 12 [
         <a href="#rid27">
          27
         </a>
         ]. Benefit was frequently seen in the first month, and a majority of patients responded within four months (three doses). Approximately 40 percent of patients became asymptomatic (ie, complete response) by week 12 and approximately 45 percent by week 24 (in the longer studies). Thus, the analysis suggested that there is a group of early responders (&lt;1 month) and a smaller group who respond later. Overall, a period of 16 weeks should be sufficient to identify patients who will benefit.
        </p>
        <p>
         A meta-analysis was performed on 67 observational studies (randomized trials were excluded) in an effort to describe the "real-world" benefits and risks of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         therapy [
         <a href="#rid28">
          28
         </a>
         ]. In contrast to a meta-analysis of randomized trials, such an analysis provides an estimate of the effects of therapy combined with possible placebo effect (see
         <a class="local">
          'Efficacy'
         </a>
         above). Outcomes were expressed as improvement in the weekly Urticaria Activity Score (UAS7), which ranges from 0 to 42, with higher scores indicating more severe symptoms. Omalizumab therapy was associated with a reduction in UAS7 scores of 26 points (95% CI 28-23 points). Approximately 72 percent of patients had a complete response, and approximately 18 percent had a partial response. The rate of adverse events was 4 percent, with three patients experiencing anaphylaxis.
        </p>
        <p class="headingAnchor" id="H935101268">
         <span class="h3">
          Dose adjustment and duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal duration of therapy has not been determined, and patients may relapse when
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         is tapered or discontinued [
         <a href="#rid24">
          24
         </a>
         ]. Approaches to tapering therapy have not been studied extensively, although an algorithm has been proposed by one group [
         <a href="#rid29">
          29
         </a>
         ]. The approach of the author and section editors is described here. We consider the severity of disease and duration of CSU, with a more gradual stepdown approach for patients with very severe or long-term CSU as well as those with inducible forms of chronic urticaria. For example, in a patient with a history of refractory CSU for many years (eg, ≥3 years) who responds to omalizumab, we would treat for a minimum of one year before considering tapering.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient has complete resolution of symptoms and no breakthrough symptoms for two to three months, the dose may be lowered (to 150 mg), and the interval between injections can be gradually lengthened. If a patient has no symptoms for a period of time on 150 mg every eight weeks, therapy can be stopped. Other experts (including the author) maintain a dose of 300 mg monthly, prolong the interval by one week per cycle, and discontinue therapy if the patient's disease remains controlled with eight-week intervals [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient has complete resolution of symptoms and no breakthrough symptoms for two to three months, the approach of the author and other experts is to lengthen the interval between doses by one week per cycle. If the patient's symptoms remain controlled with eight-week intervals, therapy can be discontinued [
         <a href="#rid30">
          30
         </a>
         ]. Another approach is to lower the dose gradually. These two approaches have not been formally compared.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with partial responses to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         at 300 mg, there is anecdotal evidence that some may have further improvement with higher doses (eg, 450 or 600 mg every four weeks) or more frequent doses (eg, 150 mg every two weeks) [
         <a href="#rid14">
          14,15,31
         </a>
         ]. A response to the increased dose should be evident after three doses. International guidelines recommend a dose increase up to 600 mg given every two weeks [
         <a href="#rid2">
          2
         </a>
         ]. However an observational study did not show improvement in CSU patients not controlled with omalizumab 600 mg every four weeks and then changed to every 600 mg every two to three weeks [
         <a href="#rid32">
          32
         </a>
         ]. The author does not recommend increasing the dose of omalizumab beyond 600 mg every four weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient has minimal or inadequate control of symptoms despite the higher doses of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , therapy should be discontinued after a four-month trial and other options explored. Alternatively, the combination of omalizumab and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         can be tried. (See
         <a class="local">
          'Combined with omalizumab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with urticaria who do not show sufficient benefit from treatment with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         in combination with high-dose antihistamines may be treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         (adults dose 3.5 to 5 mg/kg per day), in combination with omalizumab or as monotherapy [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Cyclosporine'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who were treated in the past and stopped therapy but then had a subsequent recurrence of CSU have been reported to respond to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         again, suggesting that resistance does not develop readily in most patients [
         <a href="#rid24">
          24,33,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H945273939">
         <span class="h1">
          OTHER THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who have not achieved adequate relief with the combination of higher-dose H1 antihistamines and
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         or do not have access to omalizumab, several other therapies can be tried, including
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         [
         <a href="#rid35">
          35-37
         </a>
         ].
        </p>
        <p>
         Alternative non-US Food and Drug Administration (FDA) approved agents for CSU can be divided into two groups, "immunosuppressant" agents and "antiinflammatory" agents, although there is considerable overlap between the two groups of drugs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The term "immunosuppressant" is applied to drugs that have more potent immunosuppression activity and greater potential toxicity, as well as more evidence for efficacy. We have categorized the calcineurin inhibitors and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil in this way.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Antiinflammatory" denotes a class of agents with predominantly antiinflammatory activities, which have low potential toxicity and less proven efficacy for CSU. We have applied this term to
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         With the immunosuppressant and antiinflammatory drugs described in this section, therapy is generally continued for a period of several months once control of symptoms has been achieved. We favor a longer duration of therapy before attempting to taper for patients with longstanding CSU.
        </p>
        <p>
         In the author's experience, serious adverse effects that require discontinuation of therapy are rare, and he has not observed any permanent complications from use of these agents [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3430832312">
         <span class="h2">
          Choice of agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         Of the drugs that have been studied in CSU, some have the advantage of a rapid onset of action, such as
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         , which can be helpful for patients with significant impairment in quality of life or side effects from glucocorticoids. The international guidelines emphasize cyclosporine over other agents, but the authors and editors of this topic consider a wider range of options [
         <a href="#rid1">
          1,35
         </a>
         ]. There is insufficient evidence on which to base a strong preference for one drug over another.
        </p>
        <p class="headingAnchor" id="H392476073">
         <span class="h2">
          Cyclosporine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         (and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ) has several desirable properties, including rapid onset (sometimes within days) [
         <a href="#rid38">
          38-41
         </a>
         ], a degree of efficacy comparable with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         [
         <a href="#rid5">
          5,42
         </a>
         ], and the possibility of lasting remission after treatment is discontinued [
         <a href="#rid41">
          41,43,44
         </a>
         ]. Cyclosporine has the most supporting data. However, cyclosporine has potentially serious adverse effects (ie, hypertension and kidney insufficiency), as well as unpleasant cosmetic effects with long-term use (ie, hirsutism and gingival hyperplasia), although these are less common at the doses used for CSU, which are significantly lower than the doses used for most other indications [
         <a href="#rid45">
          45
         </a>
         ]. Cyclosporine should be avoided in patients with chronic kidney disease or poorly controlled hypertension.
        </p>
        <p>
         Calcineurin inhibitors block the calcium-dependent release of and responsiveness to histamine, leukotriene C
         <sub>
          4
         </sub>
         , and other mediators in mast cells and several cell types [
         <a href="#rid46">
          46
         </a>
         ]. These agents also have anti-T lymphocyte activity [
         <a href="#rid47">
          47
         </a>
         ].
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         may also disrupt tumor necrosis factor alpha activity and secondarily inhibit neutrophil accumulation [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1716548638">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A 2018 systemic review identified 18 studies, including two randomized, controlled trials of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         for CSU [
         <a href="#rid49">
          49
         </a>
         ]. Early studies described significant improvement with relatively high doses (eg, 5 to 6 mg per kg daily), but patients often discontinued therapy because of adverse effects, with relapse of their urticaria [
         <a href="#rid42">
          42,50
         </a>
         ]. Most subsequent studies have used lower doses (eg, 2 to 4 mg per kg daily), as well as the strategy of starting high and tapering down to the lowest effective dose [
         <a href="#rid39">
          39,40,43,51-55
         </a>
         ]. Pediatric studies also used the lower dose range [
         <a href="#rid56">
          56
         </a>
         ]. A 2022 network meta-analysis noted better outcomes with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         than cyclosporine and a higher odds of adverse effects with cyclosporine than other treatment options [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         In a representative trial, 30 patients with CSU refractory to standard doses of antihistamine were randomized to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , 4 mg per kg daily, or placebo for four weeks [
         <a href="#rid58">
          58
         </a>
         ]. Initial nonresponders were offered open-label cyclosporine for four weeks. Eight of 19 (42 percent) receiving cyclosporine improved compared with none receiving placebo. In addition, 11 of 17 initial nonresponders responded after an additional four weeks of open-label treatment. Mild adverse effects were common in this study (29 of 30 subjects).
        </p>
        <p class="headingAnchor" id="H3786059314">
         <span class="h3">
          Combined with omalizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effectiveness of combining
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         at 3 mg/kg per day with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         at 300 mg every four weeks was evaluated in 21 CSU patients who had not responded to a trial of either therapy for four months [
         <a href="#rid59">
          59
         </a>
         ]. After six months of combined therapy, 16 of 21 patients had control of their CSU. Importantly, the majority of patients had improvement after two months, suggesting that it may take longer to see a response with this combined approach in patients refractory to omalizumab. The author has noted similar effectiveness using
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         and omalizumab in patients with inadequate control on omalizumab alone.
        </p>
        <p class="headingAnchor" id="H772673949">
         <span class="h3">
          Dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal dose of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         for CSU has not been determined. As recommended by the authors of the aforementioned systematic review, we also suggest starting with a dose of 3 mg per kg, divided into two doses [
         <a href="#rid49">
          49
         </a>
         ]. For most adults, this is 100 to 150 mg twice daily. Cyclosporine is available in modified and nonmodified formulations. We prefer using modified cyclosporine as it exhibits increased bioavailability and less erratic absorption. Some patients respond within one week or two, and most patients who will respond improve within three months.
        </p>
        <p>
         Blood pressure, blood urea nitrogen, and creatinine should be monitored monthly, and fasting lipids should be monitored initially and yearly for patients who remain on therapy. [
         <a href="#rid60">
          60
         </a>
         ]. Serum levels may be followed to ensure that the dose is not excessive, although we do not find this useful, because the optimal therapeutic level for CSU has not been defined, high levels are rare with the low doses we suggest, and drug levels do not seem to correlate with effectiveness in CSU.
        </p>
        <p>
         Mild adverse effects include paresthesias, gastrointestinal symptoms, and headache and are dose related. Dose reduction may eliminate them. Severe side effects are uncommon and should prompt discontinuation. They include hypertension and kidney insufficiency.
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         is contraindicated in patients with uncontrolled hypertension. (See
         <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">
          "Pharmacology of cyclosporine and tacrolimus"
         </a>
         .)
        </p>
        <p>
         The optimal duration of therapy with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         is not known. We typically treat patients at a dose required for complete or near-complete control of urticaria for three months and then taper the dose over several months as tolerated. In the majority of patients, six to nine months of treatment is adequate, although some require long-term therapy (two or three years) at the lowest effective dose [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3464212276">
         <span class="h2">
          Tacrolimus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data in support of the use of
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         in CSU are limited [
         <a href="#rid62">
          62,63
         </a>
         ]. Despite this, the author prefers tacrolimus over
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         because of an apparent lower rate of problematic side effects with it. In particular, tacrolimus does not cause the hirsutism and gingival hyperplasia that can be seen with cyclosporine. However, like cyclosporine, it should be avoided in patients with chronic kidney disease or poorly controlled hypertension. Baseline laboratories including kidney function are required prior to starting calcineurin inhibitors.
        </p>
        <p>
         We start
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         at a dose of 1 mg twice daily for one to two weeks and then increase by 1 to 2 mg increments every few weeks, up to a maximum of 3 mg twice daily. In our experience, most patients respond to doses ≤4 mg daily of tacrolimus. Higher doses with monitoring of drug levels can be used in patients who partially respond or have no response to lower doses. Similar to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , monitoring of kidney function is recommended to avoid kidney toxicity [
         <a href="#rid64">
          64-69
         </a>
         ].
        </p>
        <p>
         The largest study of
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         was a retrospective review of 36 patients treated with 45 distinct courses [
         <a href="#rid63">
          63
         </a>
         ]. Remission (ie, no urticaria for &gt;1 month after treatment was discontinued, with no need for other medications) occurred in 25 percent of courses; complete response occurred (no symptoms &gt;1 month while on tacrolimus) in 30 percent of courses; and partial response was seen in 23 percent of courses. An additional 23 percent of courses had no improvement with tacrolimus. The mean length of therapy was 9.2 months. Therapy was generally well tolerated, with gastrointestinal symptoms in eight patients, mild hypertension in three patients, and reversible elevations in serum creatinine in four patients.
        </p>
        <p class="headingAnchor" id="H1465161174">
         <span class="h2">
          Mycophenolate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         mofetil acts as an antimetabolite selectively for lymphocytes and also impairs expression of adhesion molecules and secondary leukocyte migration [
         <a href="#rid70">
          70
         </a>
         ]. Although unrelated to the calcineurin inhibitors, mycophenolate has some of the same properties with fewer reported adverse effects. However, it works more gradually than the calcineurin inhibitors, and it is rare to see an effect within days.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         mofetil is typically started at 1000 mg twice daily and may be increased by 500 mg twice daily at monthly intervals if needed, up to a maximal dose of 2000 mg twice daily. We rarely exceed 4000 mg daily. If there has been no improvement after one month of 2000 mg twice daily, we discontinue it.
        </p>
        <p>
         It is generally well tolerated. The most common problems are gastrointestinal symptoms and leukopenia. Complete blood counts (CBCs) should be performed after the first one to two weeks of therapy and then once every six to eight weeks thereafter if no cytopenias are noted. (See
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"
         </a>
         .)
        </p>
        <p>
         Very few studies are available on the use of
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         in CSU:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An open series evaluated nine patients with "severe" CSU, defined as symptoms unresponsive over a six-week period to antihistamines and/or more than two week-long courses of oral glucocorticoids. Patients were treated with
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , 1000 mg twice daily, for 12 weeks without dose escalation [
         <a href="#rid71">
          71
         </a>
         ]. Six patients experienced marked improvement in urticaria scores; all patients were able to discontinue glucocorticoids by the end of the 12-week trial; and improvement persisted for at least six months after discontinuation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another series of 19 patients, the majority of whom had not benefitted from other alternative therapies, doses ranging from 1 to 6 grams (divided into twice-daily dosing) were administered [
         <a href="#rid72">
          72
         </a>
         ]. Time to initial response ranged from one to nine weeks, and complete control of symptoms was achieved in 60 percent after a mean treatment period of 14 weeks. Subjects who tapered off the drug subsequently had remissions lasting between 2 and 16 weeks at the conclusion of the study. Gastrointestinal adverse effects occurred in 53 percent of subjects.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3177362745">
         <span class="h2">
          Sulfones (uncommonly used)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The sulfone medications
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         and
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         have both been studied in CSU. Dapsone is a sulfone antimicrobial agent. Sulfasalazine is an antiinflammatory 5-aminosalicylic acid (5-ASA) derivative. The author rarely uses sulfones since the approval of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         for CSU. However, if omalizumab is not available, the author prefers dapsone over sulfasalazine but prefers sulfasalazine for patients with underlying anemia.
        </p>
        <p class="headingAnchor" id="H164291956">
         <span class="h3">
          Dapsone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         may provide benefit in CSU by suppressing prostaglandin and leukotriene activity, interfering with release or function of neutrophil lysosomal enzymes [
         <a href="#rid73">
          73,74
         </a>
         ], disrupting integrin-mediated neutrophil adhesiveness [
         <a href="#rid75">
          75
         </a>
         ], inhibiting neutrophil recruitment and activation signals [
         <a href="#rid76">
          76
         </a>
         ], and scavenging oxygen-free radical intermediates [
         <a href="#rid77">
          77
         </a>
         ]. Dapsone has traditionally been thought to be helpful in cutaneous diseases in which neutrophils play a prominent role [
         <a href="#rid78">
          78
         </a>
         ]. Some cases of CSU have a neutrophil-rich infiltrate on biopsy, although whether this histopathologic finding predicts response to dapsone in patients with CSU is unproven.
        </p>
        <p>
         Prior to initiating
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         therapy, we check a CBC, liver function tests, and glucose-6-phosphate dehydrogenase (G6PD) levels. Dapsone can cause severe hemolytic anemia in patients with G6PD deficiency, and it is contraindicated in patients with this disorder. We also avoid this agent if the patient is already anemic or has any abnormalities in hepatic function. The various diagnostic tests for G6PD deficiency are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         In adults,
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         can be initiated at a dose of 100 mg daily. CBC and liver function tests should be checked in two weeks and repeated monthly for three months and then less often. A 10 to 20 percent decline in hemoglobin (1 to 2 grams/dL) or hematocrit is common, even in patients who do not have G6PD deficiency, and it is not necessary to stop therapy unless the decrease exceeds 25 percent. The dose can be reduced once there is a clear clinical response. A four-week trial is usually sufficient to determine effectiveness.
        </p>
        <p>
         Peripheral neuropathy, clinically significant methemoglobinemia, agranulocytosis, and drug-allergic reactions, such as drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DiHS), are rare but serious reactions that warrant immediate discontinuation of
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         [
         <a href="#rid79">
          79,80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">
          "Methemoglobinemia"
         </a>
         .)
        </p>
        <p>
         Studies indicating that
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         is effective for the treatment of CSU include two small, randomized trials [
         <a href="#rid81">
          81,82
         </a>
         ]. In the more rigorous trial, 22 patients with antihistamine-refractory CSU showed improvement in itch and urticaria scores in patients taking dapsone, 100 mg daily [
         <a href="#rid81">
          81
         </a>
         ]. In all responders, efficacy was apparent within the first week. Three patients had complete resolution of CSU with dapsone [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         A larger retrospective review included 79 patients with CSU refractory to four times the standard dose of nonsedating antihistamines [
         <a href="#rid83">
          83
         </a>
         ]. Some had additionally not improved with one or more other agents (ie, glucocorticoids,
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil, leukotriene inhibitors, H2 antagonists, and/or
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         ). Improvement was seen in 62 patients in a mean of 1.1 months, with the mean maximal dose of 118 mg daily. In addition, 29 of these individuals had complete resolution after a mean of 5.2 months.
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         was tapered down after two months of controlled symptoms, and 10 patients had sustained remission for periods up to 16 months. However, two patients developed serious adverse effects (DRESS/DiHS and methemoglobinemia).
        </p>
        <p>
         The optimal duration of treatment is unknown. If the patient is on sedating antihistamines or did not respond significantly to antihistamines in the past, we taper them first, and then the
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         is reduced over a period of several months as tolerated.
        </p>
        <p class="headingAnchor" id="H291794728">
         <span class="h3">
          Sulfasalazine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          Sulfasalazine
         </a>
         is preferable to
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         in patients with underlying anemia. In adults, sulfasalazine therapy can be initiated with 500 mg once or twice per day for one week and then gradually increased to 1 gram twice per day.
        </p>
        <p>
         Mechanisms of action with possible relevance in CSU include alteration of adenosine release [
         <a href="#rid84">
          84
         </a>
         ], decreased leukotriene and prostaglandin synthesis, inhibition of IgE-mediated mast cell degranulation [
         <a href="#rid85">
          85
         </a>
         ], attenuation of neutrophil respiratory burst [
         <a href="#rid86">
          86
         </a>
         ], and inhibition of early-phase events in the proliferation and differentiation of B lymphocytes [
         <a href="#rid87">
          87
         </a>
         ].
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          Sulfasalazine
         </a>
         is metabolized to sulfapyridine and 5-ASA within the gastrointestinal tract, and most of the 5-ASA is degraded locally in the colon without much systemic distribution. Thus, the sulfapyridine may be largely responsible for its therapeutic activity in patients with CSU.
        </p>
        <p>
         Overall,
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         is well tolerated by most patients. Side effects include nausea, headache, mild or transient leukopenia, and transaminitis. Rare reports of agranulocytosis exist. Folate supplements should be coadministered to females who are pregnant or could potentially conceive. Drawbacks include the advisability of gradual dose escalation, which may prolong the time to clinical response, as well as the need for laboratory monitoring.
        </p>
        <p>
         Laboratory monitoring with a CBC, liver function tests, and urinalysis is performed every month for the first three months and then less often. A four- to six-week trial is usually sufficient to determine effectiveness. British guidelines recommend monitoring with CBC, blood urea nitrogen, creatinine, electrolytes, and liver function tests monthly during the first three months and then every three months thereafter [
         <a href="#rid60">
          60
         </a>
         ]. Other guidelines suggested weekly or every other week blood counts and transaminases during the first month. Monitoring in patients with rheumatologic diseases is reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7524.html" rel="external">
          "Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis", section on 'Dosing and monitoring'
         </a>
         .)
        </p>
        <p>
         Observational studies suggest that
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         is useful as an add-on to standard therapies for patients with refractory symptoms [
         <a href="#rid88">
          88-92
         </a>
         ].The largest study was a retrospective chart review of 39 patients with CSU refractory to antihistamines and other therapies treated with sulfasalazine as an add-on therapy [
         <a href="#rid88">
          88
         </a>
         ]. These patients had relatively recalcitrant disease and had CSU on average for 5.5 years prior to starting sulfasalazine, during which one-third required daily glucocorticoids and 10 percent had received other immunomodulators (
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ). Sulfasalazine treatment was added to existing therapies starting with 500 mg daily and increased by 500 mg per week to 2000 mg daily if tolerated (and up to 3000 mg daily in 15 patients), and laboratories remained normal. Using this approach, 84 percent of patients improved within three months. The percentage becoming asymptomatic on sulfasalazine on the background of antihistamines was 32 and 51 percent by three and six months, respectively. The average duration of sulfasalazine therapy was 74 weeks. Nine of 10 steroid-dependent patients were able to discontinue glucocorticoids. Once the patient's symptoms were controlled, sulfasalazine was gradually withdrawn, while antihistamines were continued throughout in most patients and withdrawn last. Eleven patients remained asymptomatic after sulfasalazine was discontinued, requiring only antihistamine therapy. Five patients (16 percent) failed therapy, either due to a drug adverse effect (one) or lack of improvement. There were two serious adverse events (neutropenia and leukopenia and rhabdomyolysis of uncertain association), although both patients recovered fully after the drug was discontinued.
        </p>
        <p>
         The optimal duration of treatment is unknown. If the patient is on sedating antihistamines or did not respond significantly to antihistamines in the past, we taper them first, and then the
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         is reduced over a period of several months as tolerated.
        </p>
        <p class="headingAnchor" id="H3540444349">
         <span class="h2">
          Hydroxychloroquine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          Hydroxychloroquine
         </a>
         is an antiinflammatory drug and antimalarial agent. The relative safety and low cost of hydroxychloroquine makes it a reasonable agent in the treatment of refractory CSU. The major disadvantage is a relatively slow onset of action.
        </p>
        <p>
         In adults, we start with a dose of 200 mg twice per day. A three-month trial is usually required to determine effectiveness.
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          Hydroxychloroquine
         </a>
         rarely causes serious side effects. The most common adverse reactions are related to the gastrointestinal tract (nausea), skin (various macular lesions), and central nervous system (headache).
        </p>
        <p>
         Mechanisms of action include suppression of T lymphocyte activation [
         <a href="#rid93">
          93
         </a>
         ] and disruption of antigen processing and other cellular processes by alkalinization of intracellular vacuoles in macrophages and other antigen-presenting cells [
         <a href="#rid94">
          94
         </a>
         ].
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          Hydroxychloroquine
         </a>
         has not been shown to induce lasting remission [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Ophthalmologic problems, including corneal deposits (reversible) and retinopathy (potentially vision threatening), are possible but rare with the low daily doses of
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         used in CSU. The issue of ophthalmologic screening is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">
          "Antimalarial drugs in the treatment of rheumatic disease", section on 'Routine eye examinations'
         </a>
         .)
        </p>
        <p>
         There are limited data on efficacy. In the best available study, 18 patients with CSU were treated with a combination of therapies for CSU (H1 antihistamines, H2 antihistamines, glucocorticoids, and
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         ) and randomized to receive either
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         , 5 mg/kg daily, or no additional drug [
         <a href="#rid95">
          95
         </a>
         ]. After three months of treatment, patients in the hydroxychloroquine arm demonstrated improved quality of life. Hydroxychloroquine was well tolerated, and there was a trend (not reaching significance) toward reduced medication use and urticarial activity.
        </p>
        <p>
         A 2022 retrospective study reported outcomes in 111 antihistamine-resistant CSU patients treated initially with
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         and 134 treated with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         [
         <a href="#rid96">
          96
         </a>
         ]. After three months of therapy, 82 percent of omalizumab patients had a complete response versus 38 percent of those on hydroxychloroquine. At 12 months, a sustained complete response was seen in 82 percent for omalizumab and 66 percent for hydroxychloroquine. There were 12 patients who had partial or no response to omalizumab who were treated with hydroxychloroquine, and 8 of 12 had a complete response by 12 months. Duration of CSU was not reported in this study, and, given the observational nature of the data, it is unclear if the higher responses observed at 12 months may be due to natural remission of disease.
        </p>
        <p class="headingAnchor" id="H128287482">
         <span class="h1">
          INVESTIGATIONAL AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other biologics are under investigation for the treatment of refractory CSU, including the high-affinity anti-IgE monoclonal antibody ligelizumab [
         <a href="#rid97">
          97-99
         </a>
         ], the anti-interleukin (IL) 4 and IL-13 monoclonal
         <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">
          dupilumab
         </a>
         [
         <a href="#rid100">
          100,101
         </a>
         ], the anti-IL-5 receptor alpha monoclonal antibody
         <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">
          benralizumab
         </a>
         [
         <a href="#rid102">
          102,103
         </a>
         ], the Bruton tyrosine kinase inhibitor remibrutinib [
         <a href="#rid104">
          104
         </a>
         ], and several novel drugs that are still in development [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          RARELY USED THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are additional agents that have been reported to be useful in the management of CSU, although each has significant limitations, including one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High cost combined with limited evidence of benefit (eg,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limited evidence of benefit (eg,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid106">
          106
         </a>
         ], methylxanthines, phototherapy)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The potential for serious adverse effects (eg,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , tumor necrosis factor [TNF] inhibitors,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , antifibrinolytics, anticoagulants, androgens)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1983492322">
         <span class="h2">
          Phototherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phototherapy (eg, either psoralen plus ultraviolet A [PUVA] or narrowband ultraviolet B [UVB] and ultraviolet A [UVA]) have been shown to have modest clinical benefit in CSU [
         <a href="#rid107">
          107-110
         </a>
         ]. In a randomized trial of 50 patients with CSU refractory to H1 antihistamines (escalated to fourfold the standard dose for at least three months) and requiring repeated courses of oral glucocorticoids, subjects received either PUVA or narrowband UVB for 90 days [
         <a href="#rid111">
          111
         </a>
         ]. There was no placebo group. Subjects in both treatment groups had statistically and clinically significant improvement, with greater improvement in the UVB group, and the authors noted that most responders had continued benefit for up to one year. However, very few patients had complete control of hives, and adverse effects included tanning and xerosis of the skin. In addition, the mean IgE was quite high in this population of patients from India (403 to 721 international units/mL), raising questions regarding the generalizability of the findings.
        </p>
        <p>
         Phototherapy is a reasonable option for patients able to commit to frequent visits or for those intolerant to systemic medications. Skin that is directly irradiated improves most dramatically, suggesting local mediators and cells as primary targets. Histamine release from mast cells may also be reduced [
         <a href="#rid112">
          112
         </a>
         ]. It has also been used in the management of solar urticaria and other physical urticarias. Phototherapy and its longer-term adverse effects are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">
          "Psoralen plus ultraviolet A (PUVA) photochemotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8109.html" rel="external">
          "Physical (inducible) forms of urticaria", section on 'Solar urticaria'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3244207249">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several other agents with weak evidence of efficacy in CSU.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          Sirolimus
         </a>
         (rapamycin) was reported to be effective in two of three patients in a case report [
         <a href="#rid113">
          113
         </a>
         ]. The patients had previously not improved with multiple alternative therapies, including
         <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">
          montelukast
         </a>
         ,
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9717" href="/z/d/drug information/9717.html" rel="external">
          olsalazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          Immune globulin
         </a>
         (given intravenously or subcutaneously) may be an option in patients in whom an immunomodulator would be preferable to an immunosuppressive agent, such as those with a history of malignancy. It is an immunomodulatory agent that alters cell adhesion, immunoregulatory molecules, complement function, cytokine levels, autoantibody production, and anti-idiotypic networks [
         <a href="#rid114">
          114
         </a>
         ]. Dosing has varied in past trials. The optimal dose, number of infusions to administer, and schedule for CSU are unknown and have ranged from a single dose of 2 grams/kg to 0.15 grams/kg, given monthly [
         <a href="#rid115">
          115-122
         </a>
         ]. Similar to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , barriers to use include expense, approval by insurance carriers, and inconvenience. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TNF inhibitors, including
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         ,
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         , have been studied in the treatment of CSU because TNF-alpha has been shown to be upregulated in the epidermis in lesional and nonlesional skin of CSU patients relative to controls [
         <a href="#rid123">
          123
         </a>
         ]. We would consider TNF inhibitors in patients who have not improved with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , calcineurin inhibitors, and antiinflammatory agents. Reports of effectiveness are limited [
         <a href="#rid124">
          124,125
         </a>
         ]. In the largest series, 25 patients with CSU refractory to omalizumab,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         were treated with adalimumab or etanercept for 3 to 35 months, with responses in 10 of 17 and 5 of 8, respectively [
         <a href="#rid125">
          125
         </a>
         ]. Sixty percent obtained complete or near-complete control of symptoms. One patient experienced a severe adverse effect (polyneuropathy).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Optimal dosing of TNF inhibitors for CSU is unknown, but doses similar to those for other cutaneous diseases have been used. As with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , barriers to use include expense and inconvenience. TNF inhibitors have several adverse effects, including injection-site or infusion-related reactions, infectious complications, and others. (See
         <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of two randomized trials found that
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         had no significant benefit as an add on to antihistamines in difficult-to-treat CSU [
         <a href="#rid126">
          126
         </a>
         ]. Methotrexate reduces neutrophil accumulation in inflamed skin [
         <a href="#rid127">
          127
         </a>
         ], diminishes activated leukocyte adhesiveness and other adenosine-mediated antiinflammatory properties [
         <a href="#rid128">
          128
         </a>
         ], decreases leukotriene synthesis [
         <a href="#rid129">
          129
         </a>
         ], and alters cytokine activity [
         <a href="#rid130">
          130
         </a>
         ]. Adverse effects can be serious, and frequent monitoring is advised. These issues are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">
          "Major side effects of low-dose methotrexate"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          Colchicine
         </a>
         may act to relieve CSU by suppressing leukotriene generation or by decreasing leukocyte adhesiveness and migration, but our clinical experience with it has been disappointing [
         <a href="#rid131">
          131,132
         </a>
         ]. It has a favorable safety profile at recommended doses, minimal requirements for monitoring, and a generally rapid onset of action. However, evidence of benefit in patients with CSU is limited to anecdotal reports and retrospective series [
         <a href="#rid133">
          133-135
         </a>
         ]. The single available randomized, controlled trial evaluated 12 patients with delayed-pressure urticaria and failed to demonstrate any effect compared with placebo [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         has generally been reserved for patients in whom multiple other alternative agents have failed. It is believed to act on plasma cells to reduce autoantibody production in autoimmune CSU [
         <a href="#rid137">
          137
         </a>
         ]. Evidence of efficacy is limited to case reports of patients with positive autologous serum skin tests who had not improved despite multiple other therapies, including
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid138">
          138-140
         </a>
         ]. In one report, improvement began four weeks into the initial infusions and continued to complete resolution by six months [
         <a href="#rid138">
          138
         </a>
         ]. The patient continued to be asymptomatic 12 months after the last infusion. Cyclophosphamide use is limited by expense, inconvenience, need for monitoring, and risk of serious adverse effects (including delayed secondary neoplasia and hemorrhagic cystitis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several anticoagulants and antifibrinolytic agents have been studied in CSU because the inflammatory pathways believed relevant to urticaria/angioedema are interconnected with pathways of coagulation and fibrinolysis [
         <a href="#rid141">
          141,142
         </a>
         ]. Agents acting on different points in these pathways theoretically shunt mediators along altered routes and reduce prourticarial factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antifibrinolytic agents (aprotinin and
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         ) have long been used to treat disorders of angioedema, and their utility in some patients with CSU was first noted in the 1970s [
         <a href="#rid143">
          143-146
         </a>
         ]. The anticoagulants
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and heparin were also studied in CSU [
         <a href="#rid142">
          142,147-153
         </a>
         ]. However, the risks of these agents generally outweigh the potential benefits.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Methylxanthines have also been used to treat CSU [
         <a href="#rid154">
          154,155
         </a>
         ]. A double-blind, placebo-controlled study of 134 CSU patients evaluated
         <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">
          theophylline
         </a>
         200 mg twice daily for six months followed by 200 mg once daily for six months, as add-on therapy to
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         [
         <a href="#rid155">
          155
         </a>
         ]. Both groups experienced large improvements in all symptoms assessed, and the theophylline group had statistically significant improvement in overall urticaria scores. However, pruritus did not improve.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3512698340">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/108976.html" rel="external">
          "Society guideline links: Urticaria and angioedema (excluding hereditary angioedema)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H357723768">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86634.html" rel="external">
          "Patient education: Chronic hives (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for specialist referral
         </strong>
         – Patients with chronic spontaneous urticaria (CSU) that is not controlled by higher-dose, nonsedating H1 antihistamines in combination with other standard therapies (additional H1 antihistamines, H2 antihistamines, and/or antileukotriene drugs) should be referred to an allergy or dermatology specialist for consideration of advanced therapies rather than receiving repeated courses of oral glucocorticoids. (See
         <a class="local">
          'Overview'
         </a>
         above and
         <a class="local">
          'Referral'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Omalizumab
         </strong>
         <strong>
         </strong>
         – For patients with CSU who have significant symptoms despite maximal doses of nonsedating H1 antihistamines, we recommend adding
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         therapy in preference to other agents, with the understanding that the cost of this medication may be prohibitive in many settings (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). We initiate omalizumab at a dose of 300 mg injected subcutaneously every four weeks. (See
         <a class="local">
          'Omalizumab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other therapies
         </strong>
         – With the exception of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , the effectiveness of the other therapies discussed in this review is supported by low-quality evidence, and the approach presented is largely based on clinical experience. In addition, there are no biomarkers or clinical features that are useful in selecting one therapy over another for a specific patient. (See
         <a class="local">
          'Other therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cyclosporine
         </strong>
         <strong>
          or
         </strong>
         <strong>
          tacrolimus
         </strong>
         <strong>
         </strong>
         – For patients who have not achieved adequate relief with the combination of higher-dose H1 antihistamines and
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         or do not have access to omalizumab, we suggest a calcineurin inhibitor (ie,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We start cyclosporine at a dose of 3 mg per kg, divided into two doses daily, or tacrolimus at 1 mg twice per day. Blood pressure, blood urea nitrogen, and creatinine should be monitored. (See
         <a class="local">
          'Cyclosporine'
         </a>
         above and
         <a class="local">
          'Tacrolimus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional options
         </strong>
         – Other generally well-tolerated therapies include
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         . (See
         <a class="local">
          'Other therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018; 73:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2000; 85:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, González-Aveledo L. Biomarkers of treatment efficacy in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol 2018; 50:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy 2018; 73:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Straesser MD, Oliver E, Palacios T, et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract 2018; 6:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deza G, Bertolín-Colilla M, Pujol RM, et al. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy. Acta Derm Venereol 2017; 97:698.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration (FDA) new and generic drug approvals. http://www.fda.gov/drugs/newsevents/ucm130961.htm (Accessed on March 25, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghazanfar MN, Bartko EA, Arildsen NS, et al. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study. Clin Exp Allergy 2022; 52:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol 2019; 33:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016; 137:1742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urgert MC, van den Elzen MT, Knulst AC, et al. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol 2015; 173:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015; 135:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 2016; 71:1135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metz M, Staubach P, Bauer A, et al.. Omalizumab normalizes levels of high affinity immunoglobulin E receptor-positive skin mast cells in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled trial. J Invest Dermatol 2014; 134:S30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finlay AY, Kaplan AP, Beck LA, et al. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2017; 31:1715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gimenéz-Arnau AM, Spector S, Antonova E, et al. Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies. Clin Transl Allergy 2016; 6:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014; 150:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol 2015; 135:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghazanfar MN, Thomsen SF. Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies. Case Rep Med 2015; 2015:368053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol 2016; 137:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tharp MD, Bernstein JA, Kavati A, et al. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence. JAMA Dermatol 2019; 155:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uysal P, Eller E, Mortz CG, Bindslev-Jensen C. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized. J Allergy Clin Immunol 2014; 133:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Türk M, Maurer M, Yılmaz İ. How to discontinue omalizumab in chronic spontaneous urticaria? Allergy 2019; 74:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Türk M, Kocatürk E, Cüre K, Yılmaz İ. Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria. J Allergy Clin Immunol Pract 2018; 6:1389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alizadeh Aghdam M, van den Broek F, Rijken F, et al. High-dose omalizumab use in patients with chronic spontaneous urticaria. J Allergy Clin Immunol Pract 2020; 8:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer M, Kaplan A, Rosén K, et al. The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol 2018; 141:1138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Türk M, Yılmaz İ, Bahçecioğlu SN. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients. Allergol Int 2018; 67:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seth S, Khan DA. The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients. J Allergy Clin Immunol Pract 2017; 5:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holm JG, Ivyanskiy I, Thomsen SF. Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence. J Dermatolog Treat 2018; 29:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan DA. Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. J Allergy Clin Immunol Pract 2013; 1:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan AP. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol 2009; 123:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barlow RJ, Ross EL, MacDonald DM, et al. Treatment of severe, chronic urticaria with cyclosporin A. Eur J Dermatol 1993; 3:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ilter N, Gürer MA, Akkoca MA. Short-term oral cyclosporine for chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 1999; 12:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsland AM, Beck MH. Cold urticaria responding to systemic ciclosporin. Br J Dermatol 2003; 149:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loria MP, Dambra PP, D'Oronzio L, et al. Cyclosporin A in patients affected by chronic idiopathic urticaria: a therapeutic alternative. Immunopharmacol Immunotoxicol 2001; 23:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Gioacchino M, Di Stefano F, Cavallucci E, et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc 2003; 24:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galindo Bonilla PA, Borja Segade J, Gómez Torrijos E, Feo Brito F. Urticaria and cyclosporine. Allergy 2002; 57:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessel A, Toubi E. [Extended cyclosporine-A--treatment for severe chronic urticaria]. Harefuah 2006; 145:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marone G, Triggiani M, Cirillo R, et al. Cyclosporin A inhibits the release of histamine and peptide leukotriene C4 from human lung mast cells. Ric Clin Lab 1988; 18:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomson AW. The effects of cyclosporin A on non-T cell components of the immune system. J Autoimmun 1992; 5 Suppl A:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wershil BK, Furuta GT, Lavigne JA, et al. Dexamethasone and cyclosporin A suppress mast cell-leukocyte cytokine cascades by multiple mechanisms. Int Arch Allergy Immunol 1995; 107:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review. J Allergy Clin Immunol Pract 2018; 6:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fradin MS, Ellis CN, Goldfarb MT, Voorhees JJ. Oral cyclosporine for severe chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 1991; 25:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edström DW, Ros AM. Cyclosporin A therapy for severe solar urticaria. Photodermatol Photoimmunol Photomed 1997; 13:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toubi E, Blant A, Kessel A, Golan TD. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997; 52:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vena GA, Cassano N, Colombo D, et al. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006; 55:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessel A, Toubi E. Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy 2010; 65:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollander SM, Joo SS, Wedner HJ. Factors that predict the success of cyclosporine treatment for chronic urticaria. Ann Allergy Asthma Immunol 2011; 107:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neverman L, Weinberger M. Treatment of chronic urticaria in children with antihistamines and cyclosporine. J Allergy Clin Immunol Pract 2014; 2:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin WK, Lin SJ, Lee WR, et al. Effectiveness and Safety of Immunosuppressants and Biological Therapy for Chronic Spontaneous Urticaria: A Network Meta-Analysis. Biomedicines 2022; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grattan CE, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000; 143:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez J, Alvarez L, Cardona R. Cyclosporine and omalizumab together: A new option for chronic refractory urticaria. J Allergy Clin Immunol Pract 2020; 8:2101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chakravarty K, McDonald H, Pullar T, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2008; 47:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toubi E, Bamberger E, Kessel A. Prolonged cyclosporin-A treatment for severe chronic urticaria. Allergy 2003; 58:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessel A, Bamberger E, Toubi E. Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study. J Am Acad Dermatol 2005; 52:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorman SM Jr, Regan SB, Khan DA. Effectiveness and safety of oral tacrolimus in refractory chronic urticaria. J Allergy Clin Immunol Pract 2019; 7:2033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lykavieris P, Frauger E, Habes D, et al. Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. Transplantation 2003; 75:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Er F, Nia AM, Erdmann E. [67-year-old patient with speech disorder and dysphagia]. Dtsch Med Wochenschr 2008; 133:2463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackenzie M, Wood LA. Lingual angioedema associated with everolimus. Acta Oncol 2010; 49:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahé E, Morelon E, Lechaton S, et al. Angioedema in renal transplant recipients on sirolimus. Dermatology 2007; 214:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs U, Zittermann A, Berthold HK, et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 2005; 79:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen LK, Jensen JE, Bygum A. Second episode of near-fatal angioedema in a patient treated with everolimus. Ann Allergy Asthma Immunol 2015; 115:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moder KG. Mycophenolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol 2003; 90:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahar E, Bergman R, Guttman-Yassky E, Pollack S. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006; 45:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmerman AB, Berger EM, Elmariah SB, Soter NA. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients. J Am Acad Dermatol 2012; 66:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonney RJ, Wightman PD, Dahlgren ME, et al. Inhibition of the release of prostaglandins, leukotrienes and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis. Biochem Pharmacol 1983; 32:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozeman PM, Learn DB, Thomas EL. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol 1992; 44:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booth SA, Moody CE, Dahl MV, et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992; 98:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997; 62:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theron A, Anderson R. Investigation of the protective effects of the antioxidants ascorbate, cysteine, and dapsone on the phagocyte-mediated oxidative inactivation of human alpha-1-protease inhibitor in vitro. Am Rev Respir Dis 1985; 132:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang PG Jr. Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol 1979; 1:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosseifi SG, Guha B, Nassour DN, et al. The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. J Occup Med Toxicol 2006; 1:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sener O, Doganci L, Safali M, et al. Severe dapsone hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006; 16:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan M, Cooke A, Rogers L, et al. Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol Pract 2014; 2:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engin B, Ozdemir M. Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2008; 22:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang SE, Hoffmann R, Peterson E, Soter NA. Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria. JAMA Dermatol 2019; 155:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadangi P, Longaker M, Naime D, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996; 156:1937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1991; 36:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suematsu M, Suzuki M, Miura S, et al. Sulfasalazine and its metabolites attenuate respiratory burst of leukocytes--a possible mechanism of anti-inflammatory effects. J Clin Lab Immunol 1987; 23:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imai F, Suzuki T, Ishibashi T, Dohi Y. Effect of sulfasalazine on B cells. Clin Exp Rheumatol 1991; 9:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orden RA, Timble H, Saini SS. Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2014; 112:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGirt LY, Vasagar K, Gober LM, et al. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006; 142:1337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaffer AM. Sulfasalazine in the treatment of corticosteroid-dependent chronic idiopathic urticaria. J Allergy Clin Immunol 1991; 88:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann K, Hani N, Hinrichs R, et al. Successful sulfasalazine treatment of severe chronic idiopathic urticaria associated with pressure urticaria. Acta Derm Venereol 2001; 81:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkun Y, Shalit M. Successful treatment of delayed pressure urticaria with montelukast. Allergy 2000; 55:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman FD, Gilman AL, Hollenback C, et al. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000; 95:3460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993; 23:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reeves GE, Boyle MJ, Bonfield J, et al. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 2004; 34:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan N, Epstein TG, DuBuske I, et al. Effectiveness of Hydroxychloroquine and Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study. J Allergy Clin Immunol Pract 2022; 10:3300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for Chronic Spontaneous Urticaria. N Engl J Med 2019; 381:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen RK, Jabs F, Miehe M, et al. Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy. Allergy 2020; 75:1956.
          </a>
         </li>
         <li class="breakAll">
          Novartis. Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU). https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-ligelizumab-qge031-studies-chronic-spontaneous-urticaria-csu (Accessed on November 09, 2022).
         </li>
         <li class="breakAll">
          The trial of dupilumab for chronic spontaneous urticaria can be found at ClinicalTrials.gov, trial NCT03749135.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolkhir P, Altrichter S, Munoz M, et al. New treatments for chronic urticaria. Ann Allergy Asthma Immunol 2020; 124:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein JA, Singh U, Rao MB, et al. Benralizumab for Chronic Spontaneous Urticaria. N Engl J Med 2020; 383:1389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein JA, Singh U, Rao MB, et al. Treatment of chronic spontaneous urticaria with benralizumab: Report of primary endpoint per-protocol analysis and exploratory endpoints. Allergy 2021; 76:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain V, Giménez-Arnau A, Hayama K, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks. J Allergy Clin Immunol 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johal KJ, Saini SS. Current and emerging treatments for chronic spontaneous urticaria. Ann Allergy Asthma Immunol 2020; 125:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leducq S, Samimi M, Bernier C, et al. Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: A randomized, controlled trial. J Am Acad Dermatol 2020; 82:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berroeta L, Clark C, Ibbotson SH, et al. Narrow-band (TL-01) ultraviolet B phototherapy for chronic urticaria. Clin Exp Dermatol 2004; 29:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olafsson JH, Larkö O, Roupe G, et al. Treatment of chronic urticaria with PUVA or UVA plus placebo: a double-blind study. Arch Dermatol Res 1986; 278:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khafagy NH, Salem SA, Ghaly EG. Comparative study of systemic psoralen and ultraviolet A and narrowband ultraviolet B in treatment of chronic urticaria. Photodermatol Photoimmunol Photomed 2013; 29:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engin B, Ozdemir M, Balevi A, Mevlitoğlu I. Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial. Acta Derm Venereol 2008; 88:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishnoi A, Parsad D, Vinay K, Kumaran MS. Phototherapy using narrowband ultraviolet B and psoralen plus ultraviolet A is beneficial in steroid-dependent antihistamine-refractory chronic urticaria: a randomized, prospective observer-blinded comparative study. Br J Dermatol 2017; 176:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horio T. Indications and action mechanisms of phototherapy. J Dermatol Sci 2000; 23 Suppl 1:S17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan M. Treatment of refractory chronic urticaria with sirolimus. Arch Dermatol 2009; 145:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002; 107:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998; 138:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroiss M, Vogt T, Landthaler M, Stolz W. The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria. Acta Derm Venereol 2000; 80:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pereira C, Tavares B, Carrapatoso I, et al. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Eur Ann Allergy Clin Immunol 2007; 39:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klote MM, Nelson MR, Engler RJ. Autoimmune urticaria response to high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2005; 94:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asero R. Are IVIG for chronic unremitting urticaria effective? Allergy 2000; 55:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005; 80:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borcea A, Greaves MW. Methotrexate-induced exacerbation of urticarial vasculitis: an unusual adverse reaction. Br J Dermatol 2000; 143:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matteson EL. Interferon alpha 2a therapy for urticarial vasculitis with angioedema apparently following hepatitis A infection. J Rheumatol 1996; 23:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermes B, Prochazka AK, Haas N, et al. Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 1999; 103:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magerl M, Philipp S, Manasterski M, et al. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol 2007; 119:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther 2015; 28:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patil AD, Bingewar G, Goldust M. Efficacy of methotrexate as add on therapy to H1 antihistamine in difficult to treat chronic urticaria: A systematic review and meta-analysis of randomized clinical trials. Dermatol Ther 2020; 33:e14077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cream JJ, Pole DS. The effect of methotrexate and hydroxyurea on neutrophil chemotaxis. Br J Dermatol 1980; 102:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sperling RI, Coblyn JS, Larkin JK, et al. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 1990; 33:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerards AH, de Lathouder S, de Groot ER, et al. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly SJ, Uri AJ, Freeland HS, et al. Effects of colchicine on IgE-mediated early and late airway reactions. Chest 1995; 107:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995; 96:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tharp MD. Chronic urticaria: pathophysiology and treatment approaches. J Allergy Clin Immunol 1996; 98:S325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Criado RF, Criado PR, Martins JE, et al. Urticaria unresponsive to antihistaminic treatment: an open study of therapeutic options based on histopathologic features. J Dermatolog Treat 2008; 19:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pho LN, Eliason MJ, Regruto M, et al. Treatment of chronic urticaria with colchicine. J Drugs Dermatol 2011; 10:1423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawlor F, Black AK, Ward AM, et al. Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol 1989; 120:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donaldson VH, Bernstein DI, Wagner CJ, et al. Angioneurotic edema with acquired C1- inhibitor deficiency and autoantibody to C1- inhibitor: response to plasmapheresis and cytotoxic therapy. J Lab Clin Med 1992; 119:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein JA, Garramone SM, Lower EG. Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide. Ann Allergy Asthma Immunol 2002; 89:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asero R. Oral cyclophosphamide in a case of cyclosporin and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing. Clin Exp Dermatol 2005; 30:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eiser AR, Singh P, Shanies HM. Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis--a case report. Angiology 1997; 48:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006; 117:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med 2010; 5:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berova N, Petkov I, Andreev VC. Treatment of chronic urticaria with a proteinase (kallikrein) inhibitor. Br J Dermatol 1974; 90:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tant D. Tranexamic acid in chronic urticaria. Br Med J 1979; 1:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study. Acta Derm Venereol 1977; 57:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asero R, Tedeschi A, Cugno M. Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol 2010; 152:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplanski G, Fabrigoule M, Boulay V, et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. J Immunol 1997; 158:5435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fagiolo U, Cancian M, Bertollo L, et al. Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 1999; 103:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000; 30:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barlow RJ, Greaves MW. Warfarin in the treatment of chronic urticaria/angio-edema. Br J Dermatol 1992; 126:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chua SL, Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol 2005; 153:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahesh PA, Pudupakkam VK, Holla AD, Dande T. Effect of warfarin on chronic idiopathic urticaria. Indian J Dermatol Venereol Leprol 2009; 75:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biondi M, Reggiani M. [Theophylline in the therapy of urticaria]. G Ital Dermatol Venereol 1986; 121:LXXI.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalogeromitros D, Kempuraj D, Katsarou-Katsari A, et al. Theophylline as 'add-on' therapy to cetirizine in patients with chronic idiopathic urticaria. A randomized, double-blind, placebo-controlled pilot study. Int Arch Allergy Immunol 2006; 139:258.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8111 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29336054" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34536239" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11190256" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19772513" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17456211" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : BSACI guidelines for the management of chronic urticaria and angio-oedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29350016" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Biomarkers of treatment efficacy in patients with chronic spontaneous urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29083482" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29175369" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28303277" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28303277" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35278253" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30451325" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27040372" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21762974" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21636116" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23432142" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23810097" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25891046" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25046337" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27010957" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Omalizumab normalizes levels of high affinity immunoglobulin E receptor-positive skin mast cells in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28573683" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27540466" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24477320" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25441639" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25705229" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26483177" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30427977" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24360324" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30478912" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : How to discontinue omalizumab in chronic spontaneous urticaria?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29410306" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31678293" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : High-dose omalizumab use in patients with chronic spontaneous urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29132956" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28566225" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27746265" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The Comparative Safety of Multiple Alternative Agents in Refractory Chronic Urticaria Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28513247" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24565613" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19081615" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : What the first 10,000 patients with chronic urticaria have taught me: a personal journey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Treatment of severe, chronic urticaria with cyclosporin A
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10188157" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Short-term oral cyclosporine for chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12890231" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cold urticaria responding to systemic ciclosporin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11417848" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cyclosporin A in patients affected by chronic idiopathic urticaria: a therapeutic alternative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12974197" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12100312" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Urticaria and cyclosporine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16838894" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : [Extended cyclosporine-A--treatment for severe chronic urticaria].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2453912" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Cyclosporin A inhibits the release of histamine and peptide leukotriene C4 from human lung mast cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1503609" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The effects of cyclosporin A on non-T cell components of the immune system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7613160" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Dexamethasone and cyclosporin A suppress mast cell-leukocyte cytokine cascades by multiple mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28916431" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1810983" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Oral cyclosporine for severe chronic idiopathic urticaria and angioedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9361130" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cyclosporin A therapy for severe solar urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9140522" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17010756" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20626384" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cyclosporine-A in severe chronic urticaria: the option for long-term therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22123382" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Factors that predict the success of cyclosporine treatment for chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25017532" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Treatment of chronic urticaria in children with antihistamines and cyclosporine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36140253" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effectiveness and Safety of Immunosuppressants and Biological Therapy for Chronic Spontaneous Urticaria: A Network Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10951147" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32112923" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Cyclosporine and omalizumab together: A new option for chronic refractory urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16940305" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12757462" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Prolonged cyclosporin-A treatment for severe chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15627098" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30641147" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Effectiveness and safety of oral tacrolimus in refractory chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12544888" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19006046" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : [67-year-old patient with speech disorder and dysphagia].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20100146" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Lingual angioedema associated with everolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17377381" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Angioedema in renal transplant recipients on sirolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15849555" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26081314" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Second episode of near-fatal angioedema in a patient treated with everolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12546332" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Mycophenolate mofetil: new applications for this immunosuppressant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17040448" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21783274" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6553500" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Inhibition of the release of prostaglandins, leukotrienes and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1324677" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1732379" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Dapsone suppresses integrin-mediated neutrophil adherence function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9400824" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2998243" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Investigation of the protective effects of the antioxidants ascorbate, cysteine, and dapsone on the phagocyte-mediated oxidative inactivation of human alpha-1-protease inhibitor in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/528697" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Sulfones and sulfonamides in dermatology today.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16756657" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16889287" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Severe dapsone hypersensitivity syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25213055" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18081753" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30476976" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8596047" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1703070" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2886669" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Sulfasalazine and its metabolites attenuate respiratory burst of leukocytes--a possible mechanism of anti-inflammatory effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1678997" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effect of sulfasalazine on B cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24331396" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17043190" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1683883" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Sulfasalazine in the treatment of corticosteroid-dependent chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11411930" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Successful sulfasalazine treatment of severe chronic idiopathic urticaria associated with pressure urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10726745" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Successful treatment of delayed pressure urticaria with montelukast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10828029" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8278823" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Mechanism of action of hydroxychloroquine as an antirheumatic drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15086698" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36115542" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Effectiveness of Hydroxychloroquine and Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31577874" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Ligelizumab for Chronic Spontaneous Urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32037590" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32037590" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32037590" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31446134" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : New treatments for chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32997916" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Benralizumab for Chronic Spontaneous Urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33326617" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Treatment of chronic spontaneous urticaria with benralizumab: Report of primary endpoint per-protocol analysis and exploratory endpoints.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37866460" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31494233" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Current and emerging treatments for chronic spontaneous urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31394130" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: A randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14723739" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Narrow-band (TL-01) ultraviolet B phototherapy for chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2425755" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Treatment of chronic urticaria with PUVA or UVA plus placebo: a double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23281692" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Comparative study of systemic psoralen and ultraviolet A and narrowband ultraviolet B in treatment of chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18480923" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27258736" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Phototherapy using narrowband ultraviolet B and psoralen plus ultraviolet A is beneficial in steroid-dependent antihistamine-refractory chronic urticaria: a randomized, prospective observer-blinded comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10764986" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Indications and action mechanisms of phototherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19528416" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Treatment of refractory chronic urticaria with sirolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12460182" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Immunomodulatory action of intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9536230" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Intravenous immunoglobulin in autoimmune chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10954227" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18237000" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15765750" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Autoimmune urticaria response to high-dose intravenous immunoglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11097330" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Are IVIG for chronic unremitting urticaria effective?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15667028" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10886169" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Methotrexate-induced exacerbation of urticarial vasculitis: an unusual adverse reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8882052" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Interferon alpha 2a therapy for urticarial vasculitis with angioedema apparently following hepatitis A infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9949323" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17336621" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Successful treatment of delayed pressure urticaria with anti-TNF-alpha.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25731720" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32713068" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Efficacy of methotrexate as add on therapy to H1 antihistamine in difficult to treat chronic urticaria: A systematic review and meta-analysis of randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6966936" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : The effect of methotrexate and hydroxyurea on neutrophil chemotaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12106498" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Molecular action of methotrexate in inflammatory diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2167685" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12777636" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7535676" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Effects of colchicine on IgE-mediated early and late airway reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7543498" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8977544" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Chronic urticaria: pathophysiology and treatment approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18484427" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Urticaria unresponsive to antihistaminic treatment: an open study of therapeutic options based on histopathologic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22134566" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Treatment of chronic urticaria with colchicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2653402" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1583391" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Angioneurotic edema with acquired C1- inhibitor deficiency and autoantibody to C1- inhibitor: response to plasmapheresis and cytotoxic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12197581" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16045700" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Oral cyclophosphamide in a case of cyclosporin and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9373057" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis--a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16751006" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19949893" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4274689" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Treatment of chronic urticaria with a proteinase (kallikrein) inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/421064" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Tranexamic acid in chronic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/70935" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20203527" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16675340" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9164965" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10359897" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10931124" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Warfarin treatment of chronic idiopathic urticaria and angio-oedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1571267" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Warfarin in the treatment of chronic urticaria/angio-edema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16029359" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Chronic urticaria responding to subcutaneous heparin sodium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19293513" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Effect of warfarin on chronic idiopathic urticaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3793140" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : [Theophylline in the therapy of urticaria].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16449816" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Theophylline as 'add-on' therapy to cetirizine in patients with chronic idiopathic urticaria. A randomized, double-blind, placebo-controlled pilot study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
